Modality
Gene Therapy
MOA
VEGFi
Target
VEGF
Pathway
Epigenetic
MigrainePTSD
Development Pipeline
Preclinical
~May 2012
→ ~Aug 2013
Phase 1
~Nov 2013
→ ~Feb 2015
Phase 2
~May 2015
→ ~Aug 2016
Phase 3
~Nov 2016
→ ~Feb 2018
NDA/BLA
May 2018
→ Jun 2030
NDA/BLACurrent
NCT03201682
79 pts·PTSD
2018-05→2030-06·Active
79 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-184.2y awayPh3 Readout· PTSD
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
NDA/BLA
Active
Catalysts
Ph3 Readout
2030-06-18 · 4.2y away
PTSD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03201682 | NDA/BLA | PTSD | Active | 79 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| BGN-8936 | BeiGene | Phase 1/2 | FXIa | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF |